Doç. Dr. Özlem ÖZDEMİR

1. Leveraging the non-contrast CT component of PET/CT: an AI-driven delta-radiomics approach to monitor treatment response in metastatic breast cancer

Kahraman E. G., ÜNAL O. Ü., TAŞKAYNATAN H., ÖZDEMİR Ö., BUDAK E., SELVER M. A.

BMC Medical Imaging , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

2. Tumour–Stroma Ratio and Platinum Resistance in Epithelial Ovarian Cancer: An Exploratory Analysis

Gül G., Kutlu Ö., AYAZ D., Günenç D., ÖZDEMİR Ö., Akdemir C., et al.

Cancers , cilt.18, sa.17, 2026 (SCI-Expanded, Scopus)

3. Molecular-Like Classification in Gastric Adenocarcinomas: Correlation with Clinicopathological Features and Prognosis

Dal G., ARGON A., ÖZDEMİR Ö., İLHAN E.

International Journal of Surgical Pathology , cilt.34, sa.4, ss.858-865, 2026 (SCI-Expanded, Scopus)

4. Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study

ÖZDEMİR Ö., Günenç D., TAŞKAYNATAN H., Peker P., Kahraman E. G., Biter S., et al.

Journal of Clinical Medicine , cilt.15, sa.10, 2026 (SCI-Expanded, Scopus)

5. Magnetic resonance imaging-based artificial intelligence model predicts neoadjuvant therapy response in triple-negative breast cancer

Büyüktoka R. E., ADIBELLİ Z. H., Sürücü M., ÖZDEMİR Ö., İşler Y., Koç A. M., et al.

Diagnostic and Interventional Radiology , cilt.32, sa.2, ss.191-199, 2026 (SCI-Expanded, Scopus, TRDizin)

6. Claudin-4 Overexpression Predicts Poor Survival and Platinum Resistance in Epithelial Ovarian Cancer: A Potential Biomarker for Clinical Decision-Making †

Kutlu Ö., Günenç D., AYAZ D., ÖZDEMİR Ö., TAŞKAYNATAN H., Akdemir C., et al.

Diagnostics , cilt.15, sa.24, 2025 (SCI-Expanded, Scopus)

7. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.

Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus)

8. Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Dülgar Ö., Türker S., BAŞARAN G., Araz M., Sümbül A. T., Çağlayan D., et al.

Journal of Chemotherapy , cilt.37, sa.4, ss.334-340, 2025 (SCI-Expanded, Scopus)

9. Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

ŞAHİN T. K., Atalah F., Koylu B., Oruc A., Acarbay A., Karakok A., et al.

Frontiers in Immunology , cilt.16, 2025 (SCI-Expanded, Scopus)

10. A Comprehensive Analysis of Neoadjuvant Chemotherapy in Breast Cancer: Adverse Events, Clinical Response Rates, and Surgical and Pathological Outcomes—Bozyaka Experience

Yılmaz C., Zengel B., ÜREYEN O., ADIBELLİ Z. H., TAŞLI F., Yılmaz H. T., et al.

Cancers , cilt.17, sa.2, 2025 (SCI-Expanded, Scopus)

11. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.

BMC Cancer , cilt.24, sa.1, 2024 (SCI-Expanded, Scopus)

12. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.

BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

13. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Avcı O., İriağaç Y., Çavdar E., Karaboyun K., Araz M., Şakalar T., et al.

Journal of Geriatric Oncology , cilt.14, sa.8, 2023 (SCI-Expanded, Scopus)

14. Prognostic significance of immunhistochemical axl expression in pancreas ductal adenocarcinomas

Oz O., ARGON A., Kebat T., ÖZDEMİR Ö., YAKAN S.

Indian Journal of Pathology and Microbiology , cilt.66, sa.3, ss.533-539, 2023 (SCI-Expanded, Scopus)

15. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., BAYRAM E., Demirel B. C., et al.

Future Oncology , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)

16. The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience

Tercan I. C., Zengel B., ÖZDEMİR Ö., Cavdar D., Tasli F., ADIBELLİ Z. H., et al.

Breast Journal , cilt.2023, 2023 (SCI-Expanded, Scopus)

17. Gastrointestinal Tract Metastases of Invasive Lobular Carcinoma of the Breast: An Immunohistochemical Survey Algorithm

Zengel B., Çavdar D., ÖZDEMİR Ö., TAŞLI F., Karataş M., Şimşek C., et al.

European Journal of Breast Health , cilt.18, sa.4, ss.375-380, 2022 (Scopus, TRDizin)

18. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

ÖZDEMİR Ö., Zengel B., Yildiz Y., Uluç B. O., ÇABUK D., Ozden E., et al.

Anti-Cancer Drugs , cilt.33, sa.7, ss.663-670, 2022 (SCI-Expanded, Scopus)

19. Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients

ÖZDEMİR Ö., Zengel B., Çavdar D. K., Yilmaz C., Durusoy R.

European Journal of Breast Health , cilt.18, sa.2, ss.167-171, 2022 (Scopus, TRDizin)

20. The Importance of the Pathological Perspective in the Management of the Invasive Lobular Carcinoma

TAŞLI F., Cavdar D., Kececi S. D., Zengel B., ADIBELLİ Z. H., Dal G., et al.

Breast Journal , cilt.2022, 2022 (SCI-Expanded, Scopus)

21. The Significance of Tumor Budding and Immunohistochemical Axl Expression in Gallbladder Adenocarcinomas

Öz Ö., ARGON A., Kebat T., Akıncı Ç. N., ÖZDEMİR Ö.

Balkan Medical Journal , cilt.39, sa.3, ss.199-208, 2022 (SCI-Expanded, Scopus)

22. Prognostic importance of molecular-like classification in gastroesophageal junction tumors (Izmir Oncology Group [IZOG] study)

ÖZDEMİR Ö., ARGON A., YAKAN S., Salman T., Alacacıoğlu A.

Polish Journal of Pathology , cilt.72, sa.4, ss.315-323, 2022 (SCI-Expanded, Scopus)

23. Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes

Zengel B., KILIÇ M., TAŞLI F., Simsek C., Karatas M., ÖZDEMİR Ö., et al.

Scientific Reports , cilt.11, sa.1, 2021 (SCI-Expanded, Scopus)

24. Orbital Metastasis Secondary to Breast Cancer: A Rare Cause of Unilateral External Ophthalmoplegia

KARTI Ö., ÖZDEMİR Ö., Top Karti D., Zengin M. O., Tatli S., KÜSBECİ T., et al.

Neuro-Ophthalmology , cilt.45, sa.3, ss.181-183, 2021 (ESCI, Scopus)

25. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., BİLİCİ A., Cicin I., KÖSTEK O., Kaplan M., et al.

Cancer Chemotherapy and Pharmacology , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus)

26. Assessment of the knowledge level and behaviors of students in school of nursing about genital hygiene Hemşirelik yüksek okulu öǧrencilerinin genital hijyen hakkındaki bilgi düzeylerinin ve davranışlarının deǧerlendirilmesi

ÖZDEMİR S., Ortabaǧ T., TOSUN B., Özdemir Ö., Bebiş H.

Gulhane Medical Journal , cilt.54, sa.2, ss.120-128, 2012 (Scopus, TRDizin)